1. Home
  2. CTNM vs IMPP Comparison

CTNM vs IMPP Comparison

Compare CTNM & IMPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • IMPP
  • Stock Information
  • Founded
  • CTNM 2009
  • IMPP 1981
  • Country
  • CTNM United States
  • IMPP Greece
  • Employees
  • CTNM N/A
  • IMPP N/A
  • Industry
  • CTNM
  • IMPP Marine Transportation
  • Sector
  • CTNM
  • IMPP Consumer Discretionary
  • Exchange
  • CTNM Nasdaq
  • IMPP Nasdaq
  • Market Cap
  • CTNM 122.9M
  • IMPP 103.9M
  • IPO Year
  • CTNM 2024
  • IMPP N/A
  • Fundamental
  • Price
  • CTNM $3.85
  • IMPP $3.07
  • Analyst Decision
  • CTNM Strong Buy
  • IMPP
  • Analyst Count
  • CTNM 4
  • IMPP 0
  • Target Price
  • CTNM $22.50
  • IMPP N/A
  • AVG Volume (30 Days)
  • CTNM 222.5K
  • IMPP 395.5K
  • Earning Date
  • CTNM 08-12-2025
  • IMPP 08-26-2025
  • Dividend Yield
  • CTNM N/A
  • IMPP N/A
  • EPS Growth
  • CTNM N/A
  • IMPP N/A
  • EPS
  • CTNM N/A
  • IMPP 1.21
  • Revenue
  • CTNM N/A
  • IMPP $138,368,325.00
  • Revenue This Year
  • CTNM N/A
  • IMPP $8.79
  • Revenue Next Year
  • CTNM N/A
  • IMPP $40.11
  • P/E Ratio
  • CTNM N/A
  • IMPP $2.54
  • Revenue Growth
  • CTNM N/A
  • IMPP N/A
  • 52 Week Low
  • CTNM $3.35
  • IMPP $2.12
  • 52 Week High
  • CTNM $22.00
  • IMPP $4.55
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • IMPP 49.00
  • Support Level
  • CTNM N/A
  • IMPP $3.03
  • Resistance Level
  • CTNM N/A
  • IMPP $3.68
  • Average True Range (ATR)
  • CTNM 0.00
  • IMPP 0.24
  • MACD
  • CTNM 0.00
  • IMPP -0.05
  • Stochastic Oscillator
  • CTNM 0.00
  • IMPP 12.05

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About IMPP Imperial Petroleum Inc.

Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.

Share on Social Networks: